Study S000149

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05669755
Acronym: REDEFINE 3
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 7101
Start: 2023-03-01
Primary completion: 2027-09-01
Lead sponsor: Novo Nordisk A/S
Conditions: Cardiovascular Disease
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1270-0943; EUDRACT_NUMBER:2021-005855-35; REGISTRY:jRCT2031220672

Registered primary outcomes

Time to first occurrence of 3-point major adverse cardiovascular event (MACE), a composite endpoint consisting of: cardiovascular (CV) death, non-fatal myocardial infarction, non-fatal stroke [From baseline (week 0) to end of study (up to 242 weeks or more)]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0029336	Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3). Cavender MA, American heart journal	2026	Randomized trial	PMID 42838477 DOI	cites ClinicalTrials.gov:NCT05669755; registry reference DERIVED:42838477